What's new

Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 12, Status: Authorised

Feb 9, 2025 - 21:46
 0
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 12, Status: Authorised
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 12, Status: Authorised
Read More

Tags:

Previous Article

PSUSA/00003148/202405

Next Article

Human medicines European public assessment report (EPAR): Datroway, datopotamab ...

Related Posts

Human medicines European public assessment report (EPAR): Duloxetine Viatris (previously Duloxetine Mylan), duloxetine, Date of authorisation: 19/06/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 12, 2025  0

Human medicines European public assessment report (EPAR): Evenity, romosozumab, Date of authorisation: 09/12/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 17, 2025  0

Combination of cystic fibrosis medicines to treat patients with rare mutations

Combination of cystic fibrosis medicines to treat patie...

Feb 28, 2025  0